Angle Shares Up After New Research Released In Partnership With Illumina
Circulating Tumor Cells Analysis Found Mutations ‘Actively Spreading Cancer’
Stock prices for liquid biopsy firm Angle Plc are up since 28 January after the release of new research. The study used Angle’s technology to detect clinically relevant mutations in circulating tumor cells that were not found in traditional circulating DNA, allowing for further insights into cancer progression, Andrew Newland, Angle CEO, told Medtech Insight.
